Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
Hyper-CVAD plus ofatumumab als eerstelijnsbehandeling bij Ph-negatieve B-cel ALL
aug 2020 | Leukemie